HORMONE-RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION
Clinical trials for HORMONE-RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION explained in plain language.
Never miss a new study
Get alerted when new HORMONE-RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION trials appear
Sign up with your email to follow new studies for HORMONE-RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets genetic weakness in advanced breast cancer
Disease control OngoingThis study tests a combination of two drugs—alpelisib (a targeted therapy) and fulvestrant (a hormone blocker)—in Japanese men and postmenopausal women with a specific type of advanced breast cancer (HR+/HER2-) that has a PIK3CA mutation. The cancer must have worsened after prior…
Matched conditions: HORMONE-RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo targets Gene-Mutated breast cancer after first treatment fails
Disease control OngoingThis phase 2 trial tests whether adding alpelisib to continued fulvestrant can help people with advanced, hormone-receptor-positive, HER2-negative breast cancer that has a PIK3CA mutation. Participants have already seen their cancer progress while on fulvestrant. The study aims t…
Matched conditions: HORMONE-RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WITH PIK3CA MUTATION
Phase: PHASE2 • Sponsor: Borstkanker Onderzoek Groep • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC